Subscribe To
CYBN / Cybin, Deepak Chopra Announce Partnership For Psychedelics Awareness And Education
CYBN News
By Business Wire
September 25, 2023
Cybin to Participate in the Cantor Global Healthcare Conference
TORONTO--(BUSINESS WIRE)--Cybin Inc. (NYSE American:CYBN) (NEO:CYBN) (“Cybin” or the “Company”), a clinical-stage biopharmaceutical company co more_horizontal
By Business Wire
September 21, 2023
Cybin Announces Date of Annual and Special Meeting of Shareholders
TORONTO--(BUSINESS WIRE)--Cybin Inc. (NYSE American:CYBN) (NEO:CYBN) (“Cybin” or the “Company”), a clinical-stage biopharmaceutical company co more_horizontal
By Proactive Investors
September 20, 2023
Cybin shares continue to rise on major investment from Steve Cohen's hedge fund
Cybin Inc. (NYSE-A:CYBN, NEO:CYBN) shares maintained upward momentum on Wednesday after soaring earlier this week on the news New York Mets owner Stev more_horizontal
By Market Watch
September 18, 2023
Psychedelic stock jumps as Steve Cohen's Point72 snaps up shares
Shares of Cybin Inc., CYBN, +39.39% a developer of psychedelic therapies, finished 38.5% higher on Monday after billionaire investor and New York Mets more_horizontal
By InvestorPlace
September 14, 2023
The 3 Most Undervalued Under-$1 Stocks to Buy in September 2023
The global inflation surge and monetary policy tightening by major central banks have all contributed to the market volatility this year. Despite that more_horizontal
By Proactive Investors
June 29, 2023
Cybin narrows net loss year-over-year; eyes FDA submission in late 2023
Cybin Inc. (NYSE-A:CYBN, NEO:CYBN) reported that it has narrowed its net loss year-over-year as it has advanced its two lead clinical programs CYB003 more_horizontal
By PennyStocks
June 15, 2023
Best Penny Stocks to Buy Under $1? 4 To Watch Now
Ever find yourself daydreaming about striking it rich in the stock market? Well, buckle up, because we're about to dive headfirst into the world of pe more_horizontal
By Proactive Investors
February 15, 2023
Cybin shares rise as 3Q results meet expectations, analysts maintain ‘positive bias outlook'
Cybin Inc. (NYSE-A:CYBN, NEO:CYBN) shares moved higher just after the market opened on Wednesday after the psychedelics-focused biopharmaceutical c more_horizontal